Fagron N.V.

AGM Information • May 12, 2015

Annual General Meeting of Fagron

Fagron is pleased to announce that the Annual General Meeting of Shareholders of 11 May 2015 has approved per share proposed by the Board of Directors. The shareholders granted full discharge to the directors and the statutory auditor who were active during the financial year 2014.

lding tax.

The timetable is as follows: 14 May Ex-dividend date 15 May Record date 18 May Payment date

The Annual General Meeting of Shareholders has also made the following changes to the Board of Directors:

• Renewal of the mandates of Mr Ger van Jeveren and Mr Jan Peeters for a period of four years.
• Appointment of Ms Nathalie van Woerkom as a new Independent Director for a period of four years.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding. Fagron offers Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials to pharmacies and hospitals in 32 countries worldwide. Pharmaceutical compounding is an essential part of pharmaceutical care that enables prescribers and pharmacists to fulfil the worldwide growing need for tailor- department consists of 45 researchers and more than 300 pharmacists who are working continually on developing new concepts, vehicles and formulations to treat an increasing number of patients with tailor-made compounded medication. The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra Global Investor Relations Director Tel. +31 88 33 11 213 marieke.palstra@fagron.com investors.fagron.com